Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis
暂无分享,去创建一个
P. Bhargava | P. Calabresi | E. Mowry | L. Steinman | E. Sotirchos | C. Eckstein | A. Gocke | M. Baynes | A. Ntranos | K. V. Van Haren | Moira Baynes | Christopher Eckstein
[1] P. Bhargava,et al. 1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls , 2015, Journal of Neuroimmunology.
[2] S. Schwab,et al. Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients , 2014, PloS one.
[3] P. Bhargava,et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. , 2014, Contemporary clinical trials.
[4] Mark S. Sundrud,et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids , 2014, The Journal of experimental medicine.
[5] P. Calabresi,et al. 1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization , 2013, Proceedings of the National Academy of Sciences.
[6] C. McCulloch,et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis , 2012, Annals of neurology.
[7] A. Ponsonby,et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS , 2012, Neurology.
[8] R. Nussenblatt,et al. Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[9] F. Paul,et al. Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial , 2012, Trials.
[10] F. Barkhof,et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial , 2011, Journal of the Neurological Sciences.
[11] J. Damoiseaux,et al. Effects of vitamin D on the peripheral adaptive immune system: a review. , 2011, Autoimmunity reviews.
[12] A. Bar-Or,et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. , 2011, The Journal of clinical endocrinology and metabolism.
[13] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[14] P. Menheere,et al. Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis , 2010, PloS one.
[15] J. Correale,et al. Gender Differences in 1,25 Dihydroxyvitamin D3 Immunomodulatory Effects in Multiple Sclerosis Patients and Healthy Subjects , 2010, The Journal of Immunology.
[16] M. López-Botet,et al. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. , 2010, Clinical immunology.
[17] Maren S Fragala,et al. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research , 2010, Current opinion in clinical nutrition and metabolic care.
[18] T. Dwyer,et al. Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.
[19] E. Mowry,et al. Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis , 2010, Annals of neurology.
[20] P. Defechereux,et al. Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization , 2009, Clinical and Vaccine Immunology.
[21] L. Cosmi,et al. Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor , 2008, The Journal of experimental medicine.
[22] A. Kessels,et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.
[23] S. Gabriel,et al. Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.
[24] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[25] S. Nakae,et al. IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.
[26] K. Spach,et al. Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice1 , 2005, The Journal of Immunology.
[27] P. Calabresi,et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Bonneville,et al. Coordinated Expression of Ig-Like Inhibitory MHC Class I Receptors and Acquisition of Cytotoxic Function in Human CD8+ T Cells1 , 2004, The Journal of Immunology.
[29] R. Ravid,et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity , 2004, Annals of neurology.
[30] F. Cosman,et al. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation , 2003, Journal of Neuroimmunology.
[31] Peter A. Calabresi,et al. Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNγ-producing effector cells , 2002, Journal of Neuroimmunology.
[32] Jorge R. Oksenberg,et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.
[33] P. Kivisäkk,et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.
[34] M. Colonna,et al. A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells , 1997, The Journal of experimental medicine.
[35] H. DeLuca,et al. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] Jia Newcombe,et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.
[37] A. Shao,et al. Risk assessment for vitamin D. , 2007, The American journal of clinical nutrition.
[38] B. Steele. For More Information , 2000, Journal of the National Cancer Institute.